Completed

NIH PAR-21-338: 2024 Limited Competition: Ruth L. Kirschstein National Research Service Award (NRSA) Postdoctoral Research Training Grant for the Clinical and Translational Science Awards (CTSA) Program (T32 Clinical Trial Not Allowed)

No applicants // Limit: 1 // Tickets Available: 1 

 

The National Center for Advancing Translational Sciences (NCATS) will award Ruth L. Kirschstein National Research Service Award (NRSA) Postdoctoral Institutional Research Training Grants for the Clinical and Translational Science Awards (CTSA) Program (T32) to eligible institutions to enhance postdoctoral research training of individuals with doctoral degrees (these include, but are not limited to, the following: D.M.D., DC, DO, DVM., OD, DPM, ScD, EngD, DrPH, DNSc, DPT, PharmD, ND [Doctor of Naturopathy], DSW, PsyD, as well as a doctoral degree in nursing research) and help ensure a heterogenous pool of clinical and translational scientists trainees are equipped with the knowledge, skills and abilities to advance diagnostics, therapeutics, clinical interventions, and behavioral modifications that improve health.

NCATS will not accept applications proposing combined predoctoral and postdoctoral training under this FOA. Applications proposing predoctoral research training should apply to the Ruth L. Kirschstein National Research Service Award (NRSA) Predoctoral Institutional Research Training Grant for the Clinical and Translational Science Awards (CTSA) Program (PAR-21-337).

The proposed institutional research training program may complement other ongoing research training and career development programs at the applicant institution, but must be clearly distinct from related programs currently receiving Federal support.

 

This Funding Opportunity Announcement (FOA) does not allow appointed Trainees to lead an independent clinical trial but does allow them to obtain research experience in a clinical trial on which the PI is a mentor or co-mentor.

NCATS solicits the submission of one set of companion applications. With this solicitation for the T32 application, a separate, companion FOA solicits applications for a required UM1 (PAR-21-293: Clinical and Translational Science Award). The UM1 and initial T32 applications must be submitted concurrently; a T32 application without the required companion UM1 application will not be reviewed. The T32 application will only be awarded if the UM1 application is awarded. Resubmission of a T32 without the required UM1 will be allowed only if the UM1 application is awarded.

The sponsoring institution must assure support for the proposed program. Appropriate institutional commitment to the program includes the provision of adequate staff, facilities, and educational resources that can contribute to the planned program.

 

Funding Type
Internal Deadline
External Deadline
01/12/2024

NIH PAR-21-337: 2024 Limited Competition: Ruth L. Kirschstein National Research Service Award (NRSA) Predoctoral Research Training Grant for the Clinical and Translational Science Awards (CTSA) Program (T32 Clinical Trial Not Allowed)

No applicants  // Limit: 1 // Tickets Available: 1 

 

The National Center for Advancing Translational Sciences (NCATS) will award Ruth L. Kirschstein National Research Service Award (NRSA) Predoctoral Institutional Research Training Grants for the Clinical and Translational Science Awards (CTSA) Program (T32) to eligible institutions to enhance predoctoral research training of individuals seeking a PhD or an equivalent research health professional degree and help ensure a heterogenous pool of clinical and translational scientist trainees who are equipped with the knowledge, skills and abilities to advance diagnostics, therapeutics, clinical interventions, and behavioral modifications aimed at improving health.

Applicants interested in providing short-term research experiences to health professional participants must apply to the companion NCATS Clinical and Translational Science Award (CTSA) Program Research Education Grants Programs (R25) (PAR-21-339). A short-term research experience is one where the participant is full-time (40 hours per week) for a period of 10 to 15 weeks, or as specified by the sponsoring institution in accordance with its own policies.

The proposed institutional research training program may complement other ongoing research training and career development programs at the applicant institution, but must be clearly distinct from related programs currently receiving Federal support.

This Funding Opportunity Announcement (FOA) does not allow appointed Trainees to lead an independent clinical trial but does allow them to obtain research experience in a clinical trial on which the PI is a a mentor or co-mentor. NIH strongly supports training towards a career in clinically relevant research and so gaining experience in clinical trials under the guidance of a mentor or co-mentor is encouraged.

 

NCATS solicits the submission of one set of companion applications. With this solicitation for the T32 application, a separate, companion FOA solicits applications for a required UM1 (PAR-21-293: Clinical and Translational Science Award). The UM1 and initial T32 applications must be submitted concurrently; a T32 application without the required companion UM1 application will not be reviewed. The T32 application will only be awarded if the UM1 application is awarded. Resubmission of a T32 without the required UM1 will be allowed only if the UM1 application is awarded.

The sponsoring institution must assure support for the proposed program. Appropriate institutional commitment to the program includes the provision of adequate staff, facilities, and educational resources that can contribute to the planned program.

 

Funding Type
Internal Deadline
External Deadline
01/12/2024

NIH PAR-24-061: 2024 Nursing Research Education Program in Firearm Injury Prevention Research: Short Courses (R25 Independent Clinical Trial Not Allowed)

No applicants  // Limit: 1 // Tickets Available: 1 

 

The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH.  The overarching goal of this R25 program is to support educational activities that complement and/or enhance the training of a workforce to meet the nation’s biomedical, behavioral and clinical research needs.

To accomplish the stated over-arching goal, this NOFO will support educational activities with a primary focus on:

  • Courses for Skills Development

This R25 program will support the development and implementation of short courses to prepare nurse scientists, and scientists in aligned fields, to conduct firearm injury prevention research in support of the NINR Strategic Plan (https://www.ninr.nih.gov/aboutninr/ninr-mission-and-strategic-plan). Applications for courses that build on the existing knowledge, approaches, methods, and techniques related to injury prevention to advance research specifically in the area of firearm injury are encouraged. Proposed courses should include content related to inequities in firearm injuries (e.g., race, ethnicity, socioeconomic position, gender, geography, and their intersections) and research at the individual, community, institutional, and structural levels.

This NOFO requires a Plan for Enhancing Diverse Perspectives (PEDP), which will be assessed as part of the scientific and technical peer review evaluation. Applications that fail to include a PEDP will be considered incomplete and will be withdrawn.

Applicants are strongly encouraged to read the NOFO instructions carefully and view the available PEDP guidance material.

Funding Type
Internal Deadline
External Deadline
01/25/2024

NIH PAR-21-339: 2024 Limited Competition: NCATS Clinical and Translational Science Award (CTSA) Program Research Education Grants Programs (R25 - Clinical Trial Not Allowed)

No applicants  // Limit: 1 // Tickets Available: 1 

 

To accomplish the stated overarching goal, this FOA will provide support to recipients of Clinical and Translational Science Awards (CTSA) for creative educational activities with a primary focus on research experiences designed to ensure that the participants receive exposure to the scientific and operational principles underlying each step of the translational process so that they can apply these principles to clinical and translational science research areas such as: 1) pre-clinical research, 2) clinical research, 3) clinical implementation, and 4) public health.

  • Research Experiences

 

NCATS solicits the submission of one set of companion applications. With this solicitation for the R25 application, a separate, companion FOA solicits applications for a required UM1 (PAR-21-293: Clinical and Translational Science Award). The UM1 and initial R25 applications must be submitted concurrently; an R25 application without the required companion UM1 application will not be reviewed. The R25 application will only be awarded if the UM1 application is awarded. Resubmission of an R25 without the required UM1 will be allowed only if the UM1 application is awarded.

The sponsoring institution must assure support for the proposed program. Appropriate institutional commitment to the program includes the provision of adequate staff, facilities, and educational resources that can contribute to the planned program

The PD/PI should be an established investigator in the scientific area in which the application is targeted and capable of providing both administrative and scientific leadership to the development and implementation of the proposed program. The PD/PI will be expected to monitor and assess the program and submit all documents and reports as required.

The UM1 PD(s)/PI(s) may not be a PD(s)/PI(s) on the R25 award.

NCATS solicits the submission of one set of companion applications. With this solicitation for the R25 application, a separate, companion FOA solicits applications for a required UM1 (PAR-21-293: Clinical and Translational Science Award). The UM1 and initial R25 applications must be submitted concurrently; an R25 application without the required companion UM1 application will not be reviewed. The R25 application will only be awarded if the UM1 application is awarded. Resubmission of an R25 without the required UM1 will be allowed only if the UM1 application is awarded. The sponsoring institution must assure support for the proposed program. Appropriate institutional commitment to the program includes the provision of adequate staff, facilities, and educational resources that can contribute to the planned program

• Applicants lacking the following will be considered as not responsive. Nonresponsive applications will not be reviewed.

• New applications that are not submitted as part of the companion and required UM1 PAR-21-293 Clinical and Translational Science Award (UM1 Clinical Trial Optional).

• Resubmission of R25 Research Education applications that are not linked to a funded UM1.

 

Internal Deadline
External Deadline
01/12/2024

NIH PAR-21-336: 2023 Limited Competition: Mentored Research Career Development Program Award in Clinical and Translational Science Awards (CTSA) Program (K12 Clinical Trial Optional) - January Deadline

No applicants  // Limit: 1 // Tickets Available: 1 

 

The National Center for Advancing Translational Sciences (NCATS) will award Institutional Research Career Development (K12) programs through the Clinical and Translational Science Awards (CTSA). The purpose of this Funding Opportunity Announcement (FOA) is to encourage institutions to propose creative and innovative institutional research career development programs designed to prepare an outstanding heterogeneous pool of promising later stage postdoctoral fellows and junior faculty scholars in clinical and translational science who have made a commitment to independent research careers (i.e., tenure-track or equivalent faculty positions), and to facilitate their timely transition to more advanced support mechanisms, e.g., K08, K23, R01, R03, etc. Applicants must submit both a UM1 application to PAR-21-293: Clinical and Translational Science Award and a K12 application to this FOA.

This Funding Opportunity Announcement (FOA) allows appointment of Scholars (K12) proposing to serve as the lead investigator of an independent clinical trial; or proposing a separate ancillary clinical trial; or proposing to gain research experience in a clinical trial led by another investigator, as part of their research and career development.

 

With this solicitation for the K12 application, a separate, companion FOA solicits applications for a required UM1 (PAR-21-293). A UM1 hub application without the required companion K12 application will not be reviewed. The required K12 application will only be awarded if the UM1 application is awarded. Initial and resubmission of K12 will be accepted concurrently or if the UM1 application is awarded.

The application must provide a specific plan describing the partnership between the UM1, the required K12 and any optional components. The applicant institution must be the UM1 applicant. The UM1 institution must have a strong and high-quality research program in the area(s) proposed under this K12 FOA and must have the requisite faculty, staff, potential scholars and facilities on site to conduct the proposed institutional program. In many cases, it is anticipated that the proposed program will complement other ongoing career development programs occurring at the applicant institution and that a substantial number of program faculty will have active research projects in which participating scholars may gain relevant experiences consistent with their research interests and goal.

The sponsoring institution must assure support for the proposed program. Appropriate institutional commitment to the program includes the provision of adequate staff, facilities, and educational resources that can contribute to the planned program.

The PD/PI should be an established investigator in the scientific area in which the application is targeted and capable of providing both administrative and scientific leadership to the development and implementation of the proposed program. The PD/PI will be responsible for the selection and appointment of trainees to the approved research training program, and for the overall direction, management, administration, and evaluation of the program. The PD/PI will be expected to monitor and assess the program and submit all documents and reports as required. The PD/PI has responsibility for the day to day administration of the program and is responsible for appointing members of the Advisory Committee (when applicable), using their recommendations to determine the appropriate allotment of funds.

Only one K12 application will be awarded if the UM1 application is awarded. If the UM1 is awarded and the initial K12 is not, the K12 application may be resubmitted. If the UM1 (A0) application is not awarded, then the K12 (A0) will not be awarded.

NCATS solicits the submission of one set of companion applications. With this FOA for the K12 application, a separate, companion FOA seeks applications for a required UM1 (PAR-21-293: Clinical and Translational Science Award). The UM1 and initial K12 applications must be submitted concurrently; a K12 application without the required companion UM1 application will not be reviewed. The required K12 application will only be awarded if the UM1 application is awarded. 

Funding Type
Internal Deadline
External Deadline
01/29/2024

NISG RFA-DK-25-003: 2024 Silvio O. Conte Digestive Diseases Research Core Centers (P30 Clinical Trial Optional)

No Applicants // Limit: 1 // Tickets Available: 1 

 

This Notice of Funding Opportunity (NOFO) invites applications for Silvio O. Conte Digestive Diseases Research Core Centers (DDRCCs). The DDRCCs are part of an integrated program of digestive and liver diseases research support provided by the NIDDK.  The purpose of this Centers program is to bring together basic and clinical investigators as a means to enhance communication, collaboration, and effectiveness of ongoing research related to digestive and/or liver diseases within the NIDDK's mission.  DDRCCs are based on the core concept, whereby shared resources aimed at fostering productivity, synergy, and new research ideas among the funded investigators are supported in a cost-effective manner.  Each proposed DDRCC must be organized around a central theme that reflects the focus of the digestive or liver diseases research of the Center members. The central theme must be within the primary mission of the NIDDK, and not thematic areas for which other NIH Institutes or Centers are considered the primary source of NIH funding. 

This NOFO requires a Plan for Enhancing Diverse Perspectives (PEDP), which will be assessed as part of the scientific and technical peer review evaluation. Applications that fail to include a PEDP will be considered incomplete and will be withdrawn. Applicants are strongly encouraged to read the NOFO instructions carefully and view the available PEDP guidance material.

Funding Type
Internal Deadline
External Deadline
02/22/2024

NIH PAR-23-286: 2024 NCI Pathway to Independence Award for Early-Stage Postdoctoral Researchers (K99/R00 - Independent Clinical Trial Not Allowed)

 Limit: 4 // Tickets Available: 3 // S. Yeo (Postdoctoral UACC)

 

The purpose of the NCI Pathway to Independence Award for Early-Stage Postdoctoral Researchers (K99/R00) program is to increase and maintain a strong cohort of new and talented, NCI-supported, independent investigators. This program is designed for postdoctoral fellows with research and/or clinical doctoral degrees who do not require an extended period of mentored research training beyond their doctoral degrees. The objective of this award is to facilitate a timely transition of these fellows from their mentored, postdoctoral research positions to independent tenure-track (or equivalent) faculty positions. The program will provide independent NCI research support during this transition to help awardees to launch competitive, independent research careers. Researchers in the scientific areas of cancer control, cancer prevention and cancer data sciences are especially encouraged to work with their institutions to apply.

This Notice of Funding Opportunity (NOFO) is designed specifically for candidates proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary clinical trial. Under this NOFO candidates are permitted to propose a research experience in a clinical trial led by a mentor or co-mentor. Those proposing a clinical trial or an ancillary clinical trial as lead investigator, should apply to the companion NOFOs (PAR-23-287 or PAR-23-288).

Each eligible institution (defined as having a unique UEI number or NIH IPF number) may submit up to a combined total of four applications (one in Cancer Data Science, one in Cancer Control Science, one in Molecular/Precision Cancer Prevention, and one in Other Cancer Research) to any companion NOFO or any combination of companion NOFOs (PAR-23-286PAR-23-287, and/or PAR-23-288).

Funding Type
Internal Deadline
External Deadline
02/14/2024

NIH PAR-23-287: 2024 NCI Pathway to Independence Award for Early-Stage Postdoctoral Researchers (K99/R00 - Independent Clinical Trial Required)

No Applicants // Limit: 4 // Tickets Available: 4

 

The purpose of the NCI Pathway to Independence Award for Early-Stage Postdoctoral Researchers (K99/R00) program is to increase and maintain a strong cohort of new and talented, NCI-supported, independent investigators. This program is designed for postdoctoral fellows with research and/or clinical doctoral degrees who do not require an extended period of mentored research training beyond their doctoral degrees. The objective of this award is to facilitate a timely transition of these fellows from their mentored, postdoctoral research positions to independent tenure-track (or equivalent) faculty positions. The program will provide independent NCI research support during this transition to help awardees launch competitive, independent research careers. Researchers in the scientific areas of cancer control, cancer prevention and cancer data sciences are especially encouraged to work with their institutions to apply.

This notice of funding opportunity (NOFO) is designed specifically for candidates proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary clinical trial, as part of their research and career development. Those not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to companion NOFO (PAR-23-286).

Each eligible institution (defined as having a unique UEI number or NIH IPF number) may submit up to a combined total of four applications (one in Cancer Data Science, one in Cancer Control Science, one in Molecular/Precision Cancer Prevention, and one in Other Cancer Research) to any companion NOFO or any combination of companion NOFOs (PAR-23-286PAR-23-287, and/or PAR-23-288).

 

Funding Type
Internal Deadline
External Deadline
02/14/2024

NIH PAR-23-288: 2024 NCI Pathway to Independence Award for Early-Stage Postdoctoral Researchers (K99/R00 - Independent Basic Experimental Studies with Humans Required)

No Applicants // Limit: 4 // Tickets Available: 4

 

The purpose of the NCI Pathway to Independence Award for Early-Stage Postdoctoral Researchers (K99/R00) program is to increase and maintain a strong cohort of new and talented, NCI-supported, independent investigators. This program is designed for postdoctoral fellows with research and/or clinical doctoral degrees who do not require an extended period of mentored research training beyond their doctoral degrees. The objective of this award is to facilitate a timely transition of these fellows from their mentored, postdoctoral research positions to independent tenure-track (or equivalent) faculty positions. The program will provide independent NCI research support during this transition to help awardees launch competitive, independent research careers. Researchers in the scientific areas of cancer control, cancer prevention and cancer data sciences are especially encouraged to work with their institutions to apply.

This Notice of Funding Opportunity (NOFO) is designed specifically for candidates proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary clinical trial, as part of their research and career development. Those not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to companion NOFO (PAR-23-286).

This Notice of Funding Opportunity is for basic science experimental studies involving humans, referred to in NOT-OD-18-212 as “prospective basic science studies involving human participants.” These studies fall within the NIH definition of a clinical trial and also meet the definition of basic research. Types of studies that should be submitted under this NOFO include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind. Applicants not planning an independent clinical trial or basic experimental study with humans, or proposing to gain research experience in a clinical trial or basic experimental study with humans led by another investigator, must apply to the 'Independent Clinical Trial Not Allowed' companion NOFO.

The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions.

Each eligible institution (defined as having a unique UEI number or NIH IPF number) may submit up to a combined total of four applications (one in Cancer Data Science, one in Cancer Control Science, one in Molecular/Precision Cancer Prevention, and one in Other Cancer Research) to any companion NOFO or any combination of companion NOFOs (PAR-23-286PAR-23-287, and/or PAR-23-288).

Funding Type
Internal Deadline
External Deadline
02/14/2024

2024 Damon Runyon Clinical Investigator Award

No applicants // Limit: 5 // Tickets Available: 5

 

The University of Arizona Cancer Center (UACC) can nominate five applications for the Damon Runyon Clinical Investigator Award
For more information please contact: UACC-PreAward.

 

The Damon Runyon Clinical Investigator Award supports independent young physician-scientists conducting disease-oriented research that demonstrates a high level of innovation and creativity. The goal is to support the best young physician-scientists doing work aimed at improving the practice of cancer medicine.

The Clinical Investigator Award responds to three recognized realities:

  • Though there has never been a more pressing need or more promising time for clinical cancer research, fewer young physicians enter this area of investigation every year.
  • The number of institutions committed to training young physicians in the scientific discipline and methodologies of clinical investigation is critically low.
  • The burden of medical school debt (averaging over $100,000) discourages many physicians from pursuing clinical investigation.

The Damon Runyon Cancer Research Foundation’s award offers solutions to these realities. The awardee will receive financial support for three years, as well as assistance with certain research costs such as the purchase of equipment. The Foundation will also retire up to $100,000 of any medical school debt still owed by the awardee.

The Clinical Investigator Award program is specifically intended to provide outstanding young physicians with the resources and training structure essential to becoming successful clinical investigators. The goal is to increase the number of physicians capable of moving seamlessly between the laboratory and the patient’s bedside in search of breakthrough treatments.

Funding Type
Internal Deadline
External Deadline
01/12/2024